105 related articles for article (PubMed ID: 26458465)
1. [RASopathies and hematologic abnormalities].
Aoki Y
Rinsho Ketsueki; 2015 Oct; 56(10):2240-7. PubMed ID: 26458465
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in RASopathies.
Aoki Y; Niihori T; Inoue S; Matsubara Y
J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
[TBL] [Abstract][Full Text] [Related]
3. Modeling RASopathies with Genetically Modified Mouse Models.
Hernández-Porras I; Guerra C
Methods Mol Biol; 2017; 1487():379-408. PubMed ID: 27924582
[TBL] [Abstract][Full Text] [Related]
4. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Rauen KA; Schoyer L; Schill L; Stronach B; Albeck J; Andresen BS; Cavé H; Ellis M; Fruchtman SM; Gelb BD; Gibson CC; Gripp K; Hefner E; Huang WYC; Itkin M; Kerr B; Linardic CM; McMahon M; Oberlander B; Perlstein E; Ratner N; Rogers L; Schenck A; Shankar S; Shvartsman S; Stevenson DA; Stites EC; Stork PJS; Sun C; Therrien M; Ullian EM; Widemann BC; Yeh E; Zampino G; Zenker M; Timmer W; McCormick F
Am J Med Genet A; 2018 Dec; 176(12):2924-2929. PubMed ID: 30302932
[TBL] [Abstract][Full Text] [Related]
5. Mosaic RASopathies.
Hafner C; Groesser L
Cell Cycle; 2013 Jan; 12(1):43-50. PubMed ID: 23255105
[TBL] [Abstract][Full Text] [Related]
6. RASopathies: unraveling mechanisms with animal models.
Jindal GA; Goyal Y; Burdine RD; Rauen KA; Shvartsman SY
Dis Model Mech; 2015 Aug; 8(8):769-82. PubMed ID: 26203125
[TBL] [Abstract][Full Text] [Related]
7. [Rasopathies: developmental disorders that predispose to cancer and skin manifestations].
Hernández-Martín A; Torrelo A
Actas Dermosifiliogr; 2011; 102(6):402-16. PubMed ID: 21536246
[TBL] [Abstract][Full Text] [Related]
8. Molecular Genetics of Noonan Syndrome and RASopathies.
Liao J; Mehta L
Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):435-446. PubMed ID: 31115195
[TBL] [Abstract][Full Text] [Related]
9. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
Rauen KA; Alsaegh A; Ben-Shachar S; Berman Y; Blakeley J; Cordeiro I; Elgersma Y; Evans DG; Fisher MJ; Frayling IM; George J; Huson SM; Kerr B; Khire U; Korf B; Legius E; Messiaen L; van Minkelen R; Nampoothiri S; Ngeow J; Parada LF; Phadke S; Pillai A; Plotkin SR; Puri R; Raji A; Ramesh V; Ratner N; Shankar SP; Sharda S; Tambe A; Vikkula M; Widemann BC; Wolkenstein P; Upadhyaya M
Am J Med Genet A; 2019 Jun; 179(6):1091-1097. PubMed ID: 30908877
[TBL] [Abstract][Full Text] [Related]
10. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
Bezniakow N; Gos M; Obersztyn E
Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.
Rauen KA; Huson SM; Burkitt-Wright E; Evans DG; Farschtschi S; Ferner RE; Gutmann DH; Hanemann CO; Kerr B; Legius E; Parada LF; Patton M; Peltonen J; Ratner N; Riccardi VM; van der Vaart T; Vikkula M; Viskochil DH; Zenker M; Upadhyaya M
Am J Med Genet A; 2015 Jan; 167A(1):1-10. PubMed ID: 25393061
[TBL] [Abstract][Full Text] [Related]
12. The sixth international RASopathies symposium: Precision medicine-From promise to practice.
Gripp KW; Schill L; Schoyer L; Stronach B; Bennett AM; Blaser S; Brown A; Burdine R; Burkitt-Wright E; Castel P; Darilek S; Dias A; Dyer T; Ellis M; Erickson G; Gelb BD; Green T; Gross A; Ho A; Holder JL; Inoue SI; Jelin AC; Kennedy A; Klein R; Kontaridis MI; Magoulas P; McConnell DB; McCormick F; Neel BG; Prada CE; Rauen KA; Roberts A; Rodriguez-Viciana P; Rosen N; Rumbaugh G; Sablina A; Solman M; Tartaglia M; Thomas A; Timmer WC; Venkatachalam K; Walsh KS; Wolters PL; Yi JS; Zenker M; Ratner N
Am J Med Genet A; 2020 Mar; 182(3):597-606. PubMed ID: 31825160
[TBL] [Abstract][Full Text] [Related]
13. [Update on the treatment of RASopathies].
Duat-Rodriguez A; Hernandez-Martin A
Rev Neurol; 2017 May; 64(s03):S13-S17. PubMed ID: 28524213
[TBL] [Abstract][Full Text] [Related]
14. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
[TBL] [Abstract][Full Text] [Related]
15. RASopathies: From germline mutations to somatic and multigenic diseases.
Riller Q; Rieux-Laucat F
Biomed J; 2021 Aug; 44(4):422-432. PubMed ID: 34175492
[TBL] [Abstract][Full Text] [Related]
16. Expansion of the RASopathies.
Tidyman WE; Rauen KA
Curr Genet Med Rep; 2016 Sep; 4(3):57-64. PubMed ID: 27942422
[TBL] [Abstract][Full Text] [Related]
17. RASopathy Gene Mutations in Melanoma.
Halaban R; Krauthammer M
J Invest Dermatol; 2016 Sep; 136(9):1755-1759. PubMed ID: 27236105
[TBL] [Abstract][Full Text] [Related]
18. Pathogenetics of the RASopathies.
Tidyman WE; Rauen KA
Hum Mol Genet; 2016 Oct; 25(R2):R123-R132. PubMed ID: 27412009
[TBL] [Abstract][Full Text] [Related]
19. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
Zenker M
Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
[TBL] [Abstract][Full Text] [Related]
20. [Genetic analysis of hereditary hematological disorders: overview].
Yoshida K; Ogawa S
Rinsho Ketsueki; 2015 Jul; 56(7):861-6. PubMed ID: 26251150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
